Monitor the stock price trajectory over the next 180 days. A reverse stock split is the most likely cure if the price does not recover organically. The delisting risk may pressure the stock further, especially given the company's small market cap and lack of revenue. Watch for any reverse split announcement or other compliance plan.
Price Chart
Executive Summary
Enlivex received a Nasdaq minimum bid price deficiency notice because its ordinary shares closed below $1.00 for 30 consecutive business days. The company has 180 calendar days (until November 9, 2026) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, with a potential second 180-day cure period if eligible. This delisting risk is a material negative signal for a clinical-stage biotech with a $176M market cap and no approved products.
Key Facts
- Nasdaq notified Enlivex that its closing bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- Initial compliance period ends November 9, 2026; a second 180-day period may be available if the company meets other listing standards.
- Failure to cure could lead to delisting from Nasdaq, with an opportunity to appeal to a Hearings Panel.
- The notice has no immediate effect on trading or business operations, but delisting risk is now a material overhang.
- Enlivex is a clinical-stage company with no approved products and a treasury strategy centered on the RAIN token.
Financial Impact
Delisting risk creates a material overhang on the stock; no specific dollar amounts disclosed in the filing.
Risk Factors
- Failure to regain compliance by November 9, 2026 could lead to delisting from Nasdaq.
- A reverse stock split, if needed, could be viewed negatively by the market and may not address underlying business challenges.
- The company's treasury strategy centered on the RAIN token introduces additional volatility and correlation risk with crypto markets.
- Clinical-stage biotech with no approved products; any setback in Allocetra development could compound the delisting risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-057782 |
| Document: ea0290815-6k_enlivex.htm | 0001213900-26-057782 |
| Document: 0001213900-26-057782-index-headers.html | 0001213900-26-057782 |
| Document: 0001213900-26-057782-index.html | 0001213900-26-057782 |
| Document: 0001213900-26-057782.txt | 0001213900-26-057782 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.71 (−1462.86%) |
Oct 22, 2026 4d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.71 (+1462.86%) |
Oct 22, 2026 4d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.71 (+1462.86%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.71 (−1209.18%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.71 (−1209.18%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.71 (+427.24%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.71 (+319.25%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.71 (+71.52%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.71 (+38.97%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.71 (+20.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers